Proteus mirabilis Vaccines
Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against disease caused by Proteus mirabilis and guarantee the finest results for our customers all over the world.
Proteus mirabilis (P. mirabilis) is a ubiquitous gram-negative, facultative anaerobe with an ability to ferment maltose and inability to ferment lactose which is a part of the Enterobacteriaceae family of Bacilli. The bacterium also has a swarming motility and the ability to self-elongate and secrete a polysaccharide when in contact with solid surfaces; this allows for attachment and easy motility along surfaces. P. mirabilis has been suggested as a possible causative agent of outbreaks of gastroenteritis, resulting from the consumption of contaminated food. The most common clinical manifestations are urinary tract infections (UTIs) which can result in kidney stones, over time they may grow large enough to cause obstruction and renal failure.
Inactivated P. mirabilis Vaccines
Scientists have found that Proteus-like (MR/P) fimbriae elicited an immune response and reasoned that these fimbriae were produced in vivo and were surface exposed and could serve as an excellent candidate for vaccination. So, a vaccine was established with formalin-killed P. mirabilis or purified mannose-resistant, MR/P fimbriae, a surface antigen expressed by P. mirabilis during experimental urinary tract infection, via four routes of immunization. It boosts the immune response and perhaps uses specific protein components of the fimbria. After the vaccination of CBA mice, studies with whole fimbriae using different routes of infection including intraperitoneal, subcutaneous, intranasal, oral, and transurethral were useful in identifying the efficiency of the immune. Indeed, the intranasal route was the only group with immunoglobulin in the urine and bladder directed against P. mirabilis.
Another vaccine candidate is MrpH which is the tip adhesin of MR/P fimbria and has proven encouraging. Intranasal vaccination with this polypeptide provided significant protection against challenge. Given the functional importance of MrpH, the increased specific immune response to MrpH would result in more effective protection of mice from urinary infection by P. mirabilis. Highly significant IgG responses to MrpH vaccination were observed in the serum, bladder, and kidney and clearly measurable responses were quantified in urine and vaginal washes. The latter responses rose in response to vaccination and primary and secondary boost. Significant IgA responses were also noted in serum, vaginal wash, and kidneys. These data indicate the MrpH is also an option in vaccine development for against P. mirabilis.
Creative Biolabs is a highly proactive, robust and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against typhoid fever caused by Proteus mirabilis. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
